Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 17, pg 35, 2018)

被引:2
|
作者
van Schaik, I. N.
Bril, V
van Geloven, N.
机构
[1] Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam
[2] Department of Medicine (Neurology), University Health Network, University of Toronto, Toronto, ON
[3] Department of Biostatistics and Bioinformatics, Leiden University Medical Center, Leiden
[4] Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf
[5] Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA
[6] Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya
[7] CSL Behring, Marburg
[8] CSL Behring, King of Prussia, PA
[9] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
[10] Department of Neurology, Maastricht University Medical Center, Maastricht
来源
LANCET NEUROLOGY | 2018年 / 17卷 / 01期
基金
日本学术振兴会;
关键词
D O I
10.1016/S1474-4422(17)30378-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo. Methods Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan. Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible. We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks. We did randomisation in a 1:1:1 ratio with an interactive voice and web response system with a block size of six, stratified by region (Japan or non-Japan). The primary outcome was the proportion of patients with a CIDP relapse or who were withdrawn for any other reason during 24 weeks of treatment. Patients, caregivers, and study personnel, including those assessing outcomes, were masked to treatment assignment. Analyses were done in the intention-to-treat and per-protocol sets. This trial is registered with ClinicalTrials.gov, number NCT01545076. Findings In this randomised, double-blind, placebo-controlled trial, we randomly allocated 172 patients: 57 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (34%) to the high-dose group. In the intention-to-treat set, 36 (63% [95% CI 50–74]) patients on placebo, 22 (39% [27–52]) on low-dose SCIg, and 19 (33% [22–46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007). Absolute risk reductions were 25% (95% CI 6–41) for low-dose versus placebo (p=0·007), 30% (12–46) for high-dose versus placebo (p=0·001), and 6% (−11 to 23) for high-dose versus low-dose (p=0·32). Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group). Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo group, three (5%) in the low-dose group, and two (3%) in the high-dose group; only one (an acute allergic skin reaction in the low-dose group) was assessed to be causally related. Interpretation This study, which is to our knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerated, suggesting that SCIg can be used as a maintenance treatment for CIDP. Funding CSL Behring. © 2018 Elsevier Ltd
引用
收藏
页码:26 / 26
页数:1
相关论文
共 50 条
  • [31] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, Dinesh
    Lin, Celia J. F.
    Furst, Daniel E.
    Goldin, Jonathan
    Kim, Grace
    Kuwana, Masataka
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Distler, Oliver
    Shima, Yoshihito
    van Laar, Jacob M.
    Spotswood, Helen
    Wagner, Bridget
    Siegel, Jeffrey
    Denton, Christopher P.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : E29 - E29
  • [32] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Furst, Daniel E.
    Goldin, Jonathan
    Kim, Grace
    Kuwana, Masataka
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Distler, Oliver
    Shima, Yoshihito
    van Laar, Jacob M.
    Spotswood, Helen
    Wagner, Bridget
    Siegel, Jeffrey
    Jahreis, Angelika
    Denton, Christopher P.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : 963 - 974
  • [33] Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
    Chanan-Khan, Asher A.
    Zaritskey, Andrey
    Egyed, Miklos
    Vokurka, Samuel
    Semochkin, Sergey
    Schuh, Anna
    Kassis, Jeannine
    Simpson, David
    Zhang, Jennie
    Purse, Brendan
    Foa, Robin
    LANCET HAEMATOLOGY, 2017, 4 (11): : E534 - E543
  • [34] EFFICACY AND SAFETY OF PRUCALOPRIDE IN MEN WITH CHRONIC CONSTIPATION: A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Yiannakou, Y.
    Bouchoucha, M.
    Schiefke, I.
    Piessevaux, H.
    Filip, R.
    Gabalec, L.
    Stephenson, D.
    Kerstens, R.
    Etherson, K.
    Levine, A.
    GUT, 2015, 64 : A323 - A324
  • [35] Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Han, Joseph K.
    Bachert, Claus
    Fokkens, Wytske
    Desrosiers, Martin
    Wagenmann, Martin
    Lee, Stella E.
    Smith, Steven G.
    Martin, Neil
    Mayer, Bhabita
    Yancey, Steven W.
    Sousa, Ana R.
    Chan, Robert
    Hopkins, Claire
    LANCET RESPIRATORY MEDICINE, 2021, 9 (10): : 1141 - 1153
  • [36] Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial
    Ryan, Nicole M.
    Birring, Surinder S.
    Gibson, Peter G.
    LANCET, 2012, 380 (9853): : 1583 - 1589
  • [37] INTRAVENOUS IMMUNOGLOBULIN OVERTREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: A DOUBLE-BLIND, RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL (IOC TRIAL)
    Eftimov, F.
    Adrichem, M. E.
    de Haan, R. J.
    Dijkgraaf, M. G. W.
    Merkies, I. S. J.
    Vrancken, A. F. J.
    Notermans, N. C.
    Faber, C. G.
    van Doom, P. A.
    van Schaik, I. N.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 135 - 135
  • [38] Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial
    Gionchetti, P
    Rizzello, F
    Venturi, A
    Brigidi, P
    Matteuzzi, D
    Bazzocchi, G
    Poggioli, G
    Miglioli, M
    Campieri, M
    GASTROENTEROLOGY, 2000, 119 (02) : 305 - 309
  • [39] Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
    Schottenfeld, Richard S.
    Chawarski, Marek C.
    Mazlan, Mahmud
    LANCET, 2008, 371 (9631): : 2192 - 2200
  • [40] Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
    Croop, Robert
    Lipton, Richard B.
    Kudrow, David
    Stock, David A.
    Kamen, Lisa
    Conway, Charles M.
    Stock, Elyse G.
    Coric, Vladimir
    Goadsby, Peter J.
    LANCET, 2021, 397 (10268): : 51 - 60